# Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

> **NCT03564288** · PHASE1 · COMPLETED · sponsor: **Oscotec Inc.** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** SKI-G-801

## Key facts

- **NCT ID:** NCT03564288
- **Lead sponsor:** Oscotec Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-23
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564288, "Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03564288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*